Page last updated: 2024-11-01

nimodipine and Glaucoma

nimodipine has been researched along with Glaucoma in 2 studies

Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.
nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.

Glaucoma: An ocular disease, occurring in many forms, having as its primary characteristics an unstable or a sustained increase in the intraocular pressure which the eye cannot withstand without damage to its structure or impairment of its function. The consequences of the increased pressure may be manifested in a variety of symptoms, depending upon type and severity, such as excavation of the optic disk, hardness of the eyeball, corneal anesthesia, reduced visual acuity, seeing of colored halos around lights, disturbed dark adaptation, visual field defects, and headaches. (Dictionary of Visual Science, 4th ed)

Research Excerpts

ExcerptRelevanceReference
"Preparation and evaluation of topical ophthalmic formulations containing nimodipine-CD complexes prepared using HP-β-CD, SBE-β-CD and M-β-CD for the management of glaucoma."7.85Nimodipine Ophthalmic Formulations for Management of Glaucoma. ( Abd-Elgawad, AH; El-Dahan, MS; Jablonski, MM; Maria, DN; Soliman, OA, 2017)
"Preparation and evaluation of topical ophthalmic formulations containing nimodipine-CD complexes prepared using HP-β-CD, SBE-β-CD and M-β-CD for the management of glaucoma."3.85Nimodipine Ophthalmic Formulations for Management of Glaucoma. ( Abd-Elgawad, AH; El-Dahan, MS; Jablonski, MM; Maria, DN; Soliman, OA, 2017)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Maria, DN1
Abd-Elgawad, AH1
Soliman, OA1
El-Dahan, MS1
Jablonski, MM1
Grehn, F1

Other Studies

2 other studies available for nimodipine and Glaucoma

ArticleYear
Nimodipine Ophthalmic Formulations for Management of Glaucoma.
    Pharmaceutical research, 2017, Volume: 34, Issue:4

    Topics: 2-Hydroxypropyl-beta-cyclodextrin; Administration, Ophthalmic; Animals; beta-Cyclodextrins; Chemistr

2017
[Prospects for neuroprotective glaucoma therapy].
    Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft, 2001, Volume: 98, Issue:10

    Topics: Adrenergic alpha-Agonists; Adrenergic beta-Antagonists; Animals; Antihypertensive Agents; Apoptosis;

2001